Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07814872) titled 'A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment' on Sept. 6.
Study Type: Observational
Primary Sponsor: Harvard Medical School (HMS and HSDM)
Condition:
Neoplasms (Cancer / Tumors)
Colorectal Neoplasms
Lung Neoplasms
Endometrial Neoplasms
Breast Neoplasms
Pancreatic Neoplasms
Head and Neck Neoplasms
Kidney Neoplasms
Glioma
Ovarian Neoplasms
Stomach Neoplasms
Recruitment Status: Not recruiting
Date of First Enrollment: September 2026
Target Sample Size: 30000
Countries of Recruitment:
United States
To know more, visit ...